Targets › MUC17
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.
Probably plays a role in maintaining homeostasis on mucosal surfaces. (UniProt, Q685J3)
Open in Phaseline: the race on MUC17, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shenyang Sunshine Pharmaceutical | SSS59 humanized antibody targeting MUC17 | MUC17 | Phase 1 | Malignant Tumors | Mar 2027 |
| Suzhou Zelgen Biopharmaceuticals | ZGGS34 anti-MUC17 monoclonal antibody | MUC17 | Phase 1 | Solid Tumor | Dec 2028 |
Solid Tumor (1) Malignant Tumors (1)
protein or peptide (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.